Misleading information about Meda's share price from Six

Misleading information about Meda's share price from Six 

Today marks the first day that Meda's stock, which is listed at the OMX Nordic
Stock Exchange, is traded without the right to subscription rights in the coming
new share issue, which gives a theoretical lower share price when revalued. Six
AB has not in a correct way adjusted for this technical effect when it reports a
share price decline compared to the previous trading day. Six AB supply stock
information to news media, such a Dagens Industri.

Meda finds it urgent to inform the market about this situation to avoid
misinterpretation by existing and potential shareholders in the current new
share issue process.


For more information, please contact:

Anders Larnholt, Vice President Investor Relations, tel. +46 709 458 878


MEDA AB (publ) is a leading international specialty pharma company. The company
specialises in marketing and pharmaceutical development in late clinical stage.
Acquisitions and long-term partnerships are fundamental factors that drive the
company's strategy. Meda is represented by its own organisations in about 40
countries. Meda's products are sold in 120 countries worldwide. The Meda share
is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit
www.meda.se.